Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026GlobeNewsWire · Oct 15, 2026
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 MillionGlobeNewsWire · Sep 24, 2026
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®Business Wire · Sep 22, 2026
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare PartnersPRNewsWire · Sep 22, 2026
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 MillionGlobeNewsWire · Sep 22, 2026Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $2.01 | $2.37 | Beat |
| May 14, 2026 | $1.84 | $1.63 | Miss |
| Feb 26, 2026 | $1.46 | $2.02 | Beat |
| Nov 6, 2025 | $1.97 | $3.09 | Beat |
| Aug 7, 2025 | $1.42 | $1.60 | Beat |
| May 8, 2025 | $1.21 | $1.33 | Beat |